The health system and startup studio's new joint venture will develop and launch companies that use artificial intelligence to address healthcare problems, including disparities in care. The venture will combine Northwell's clinical expertise and patient data with Aegis' data scientists and commercialization capabilities.
The hedge fund administrator SS&C Technologies Holdings will be the majority stakeholder, while the two payers will each hold a minority interest in the joint venture, dubbed DomaniRx. The company will develop a claims adjudication platform to support its operations.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Virginia-based health system is teaming up with BAYADA Home Health Care to create a new company providing home-based and hospice care. BAYADA will oversee the day-to-day operations of the company, while VCU Health will collaborate on overall quality and safety.
The new joint venture will bring K Health's artificial intelligence-driven technology to the consumer, employer and insurer markets. The solution enables patients to understand their symptoms and connect with a doctor if needed.
Mayo Clinic struck joint ventures with two startups to develop and commercialize AI diagnostic tools. It’s part of a broader plan by Mayo Clinic to develop more AI tools to support clinical decisions.
Private equity firm Welsh, Carson, Anderson & Stowe will contribute $600 million to a joint venture with Humana. The funds will be used to develop primary care centers for Medicare patients under Humana’s Partners in Primary Care subsidiary.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The potential rewards for drugmakers' investments in pharmaceuticals and vaccines are enormous, but so are the risks, an industry consultant said.
The British drugmaker plans to separate the consumer health joint venture with Pfizer announced Wednesday three years after the transaction closes.